Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pevonedistat Alone and with Azacitidine in East Asian AML/MDS
NCT02782468Phase 1Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- May 2016
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of pevonedistat in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (4 arms), sponsored by Millennium Pharmaceuticals. Primary endpoints: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), Number of Participants With Dose Limiting Toxicities (DLTs) at Cycle 1 and 4 more. Started May 2016; status: completed.
02
Drugs
pevonedistat
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02782468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02782468.